Summary of the Company’s Response

Dr. Reddy's Laboratories Ltd. has responded to a clarification sought by the National Stock Exchange of India Ltd. (NSE) regarding a news article. The company confirmed the accuracy of the news item and provided details about its expanded collaboration with Gilead Sciences.

Date of Communication and Nature of Query

  • Date of Company's Response: September 18, 2026
  • Date of NSE Query: September 17, 2026 (Ref. No.: NSE/CM/Surveillance/17557)
  • Nature of Query: The NSE sought clarification on a news article published on Websitewww.economictimes.com on September 17, 2026, captioned "Dr Reddy's gets voluntary license for Gilead's once-yearly HIV prevention drug."

Company’s Clarification on the News Item

  • The company confirmed that the news item is correct and pertains to its press release dated September 17, 2026, titled "Dr. Reddy's expands collaboration with Gilead Sciences through voluntary licensing agreement for investigational once-yearly lenacapavir for HIV prevention."
  • The company provided specific clarifications on points raised by the exchange:
  • Negotiations/Events: Not Applicable.
  • Awareness of Undisclosed Information: The company stated that at this stage, there is no material event/information pertaining to the matter that requires disclosure under Regulation 30 of the SEBI Listing Regulations.
  • Material Impact: Not Applicable.

Reference to Regulatory Compliance

  • The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • The company explicitly stated that the matter does not constitute a material event or information requiring disclosure under this regulation.
  • The company affirmed its compliance with SEBI Listing Regulations, stating it makes timely disclosures of all events and information considered material.

Details of Financial Results Clarification

This document does not discuss or provide clarification on financial results. The communication is solely focused on clarifying a news item related to a licensing agreement.